| Company/Division name | US Pharmacopeia |
| Parent company | US Pharmacopeia |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2025 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Rockville |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Eco-system synergies, Lead time/Time to market, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |
